Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_provenance.
• NP375936.RAxZTPUCncyKr68mhKlspCCUOcyAVfANd8uCHGfhnRGtw130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP375936.RAxZTPUCncyKr68mhKlspCCUOcyAVfANd8uCHGfhnRGtw130_provenance.
• NP340122.RAXbCSUqt8uauPApehNlPw-BiBEm_IvYOCIxm3HUk7gKY130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340122.RAXbCSUqt8uauPApehNlPw-BiBEm_IvYOCIxm3HUk7gKY130_provenance.
• NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
• assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP471198.RAHagrs1BlaxrxZuXD1yjXqhXCmLq9ecMP6Any24gIg-8130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471198.RAHagrs1BlaxrxZuXD1yjXqhXCmLq9ecMP6Any24gIg-8130_provenance.
• NP646032.RAeCiSfOJ861u4ObhBy99RMf5I63PnRD7MY_XJuQty1jk130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646032.RAeCiSfOJ861u4ObhBy99RMf5I63PnRD7MY_XJuQty1jk130_provenance.
• NP397338.RAAmplUrX0fmmJCooXsyn9880jV9OAl65LvCuo3oXcAgc130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP397338.RAAmplUrX0fmmJCooXsyn9880jV9OAl65LvCuo3oXcAgc130_provenance.
• NP397260.RApVJ8n4LJEpdMjX8y858oCbo-rk1ZFZUZzEky0gPJoqw130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP397260.RApVJ8n4LJEpdMjX8y858oCbo-rk1ZFZUZzEky0gPJoqw130_provenance.
• NP397480.RAnR_xdAcHm3D_AS1nmlT6yQBJ1q77eenhWAvBpucN4Lc130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP397480.RAnR_xdAcHm3D_AS1nmlT6yQBJ1q77eenhWAvBpucN4Lc130_provenance.
• NP397012.RAEFSgleZk9JeQT6TNvFlWAPoI5YgoFFd6mlsMqeyMNhE130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP397012.RAEFSgleZk9JeQT6TNvFlWAPoI5YgoFFd6mlsMqeyMNhE130_provenance.
• NP646030.RAx8K8hpm0MHF-xeGCOmeb6TZ1qy23zTCKkgdlVO5ATig130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646030.RAx8K8hpm0MHF-xeGCOmeb6TZ1qy23zTCKkgdlVO5ATig130_provenance.
• NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646031.RAwXoZKSjQL59IrnBzaQSlsoABurhmzjlB_M_UcrGhhTU130_provenance.
• NP646034.RA4R2vdYmaweOLGPE97OOnBhPb2WyyB18VDOj2fDsVW0Y130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646034.RA4R2vdYmaweOLGPE97OOnBhPb2WyyB18VDOj2fDsVW0Y130_provenance.